Background-Delayed hyperenhancement (DHE) of the pericardium usually represents ongoing inflammation and may identify patients with constrictive pericarditis that will improve with anti-inflammatory therapy. However, a quantitative assessment of pericardial DHE has not been performed, and the hierarchical relationship among clinical factors, inflammatory markers, and pericardial DHE is unknown. Methods and Results-We identified 41 consecutive patients with constrictive pericarditis who had a cardiovascular magnetic resonance study with DHE prior to the initiation of anti-inflammatory medications. Pericardial inflammation was quantified on short-axis DHE sequences by contouring the pericardium, selecting normal septal myocardium as a reference region, and then quantifying the pericardial signal that was >6 SD above the reference. Our primary outcome was clinical improvement with anti-inflammatory therapy. The mean age of our patients was 58 years, most patients were male (83%) with New York Heart Association Class II or III (59%) heart failure, and the median follow-up was 1 year. Chest pain, lower New York Heart Association class, higher Westergren sedimentation rates, and increased pericardial DHE were all significantly associated with clinical improvement (P<0.01 for all). When quantitative pericardial DHE was added to a model that included age, chest pain, New York Heart Association class, and Westergren sedimentation rates, the global χ 
C onstrictive pericarditis, by leading to noncompliant cardiac chambers and dissociation of intrathoracic and intracardiac pressures, can result in debilitating diastolic heart failure that is refractory to diuretic therapy and often requires pericardiectomy. 1 Although pericardiectomy can be curative, surgery is frequently high-risk, 2 and some patients may resolve with medical therapy directed at the inflamed pericardium, an entity known as transient or reversible constrictive pericarditis. 3 
See Clinical Perspective
Cardiac magnetic resonance (CMR) with an assessment for delayed hyperenhancement (DHE) of the pericardium has recently emerged as a modality to identify patients with constrictive pericarditis who may respond to anti-inflammatory therapy. 4 Patients with pericardial DHE are more likely to have organizing pericarditis with fibroblast proliferation and neovascularization, whereas patients without pericardial DHE are more likely to have increased fibrosis and decreased vascularity. 5 Therefore, patients with constrictive pericarditis and significant pericardial DHE may be modifiable with anti-inflammatory therapy, whereas patients without significant pericardial DHE may already have advanced fibrosis. However, assessment of pericardial DHE has been limited to qualitative reporting of intensity and measurements of pericardial thickness. A quantitative evaluation of the magnitude of pericardial DHE may provide additional insight, and quantitative DHE has demonstrated prognostic value in myocardial diseases. [6] [7] [8] In addition, the hierarchical relationship among clinical factors, inflammatory markers, and imaging variables to predict outcomes in patients with constrictive pericarditis is uncertain. Therefore, the aim of the present study was to Pericardial Delayed Hyperenhancement in Constrictive Pericarditis evaluate the incremental prognostic value of a novel quantitative assessment of pericardial DHE to predict outcomes in patients with constrictive pericarditis.
Methods

Study Sample
From December 2008 through June 2013, we identified consecutive patients with constrictive pericarditis who had at least 3 months of clinical follow-up, an echocardiogram, and a CMR study with DHE. All patients had clinical evidence of constrictive pericarditis, a diastolic septal bounce on echocardiography, and at least 1 of the following findings of constrictive pericarditis: septal e′ >9 cm/s, prominent diastolic flow reversal in hepatic veins during expiration, >25% decrease in mitral inflow velocity or >40% increase in tricuspid inflow velocity in the first beat after inspiration, annulus reversus, or early diastolic septal inversion with inspiration during real-time cine CMR. [9] [10] [11] Patients were excluded if they were on anti-inflammatory therapy before CMR or if they were referred for pericardiectomy within 3 months of the initial visit. A total of 129 patients were diagnosed with constrictive pericarditis and had CMR with DHE. From these patients, 47 were excluded as they were referred directly for pericardiectomy. Of the remaining patients, 31 were excluded because they never received anti-inflammatory therapy. Another 10 patients were exluded because they did not have adequate follow-up or received anti-inflammatory therapy before CMR, leaving a final cohort of 41 patients (Figure 1 ).
Clinical and demographic data were obtained via manual extraction from electronic medical records. Clinical data included New York Heart Association (NYHA) class, chest pain, lower extremity edema, jugular venous distention, and baseline medication use. Comorbidities included hypertension and diabetes mellitus requiring medication, coronary artery disease as determined by >50% obstruction on angiography or history of prior myocardial infarction, and valvular heart disease requiring surgery. Anti-inflammatory therapy included colchicine, nonsteroidal anti-inflammatories (NSAIDs), and glucocorticoids.
Echocardiography and CMR
All patients had complete echocardiograms with respirometers according to established guidelines for patients with pericardial diseases. 9 CMR studies were performed on a 1.5 T MRI scanner (Achieva XR, Philips Medical Systems, Best, the Netherlands), and all imaging was performed using commercially available software, electrocardiographic triggering, and dedicated phased-array receiver coils as previously described. 5 In brief, DHE images were obtained in long-and shortaxis orientations ≈10 minutes after the intravenous injection of Gddiethylenetriamine penta-acetic acid (0.1-0.2 mmol/kg body weight) using a phase-sensitive inversion recovery technique, and inversion time was selected for optimal nulling of the myocardium. The in-plane spatial resolution of DHE images was ≈2 mm. Qualitative assessment of pericardial DHE was graded as none, mild, moderate, or severe by Level III expert readers aware of clinical information. For quantitative analysis, one author (P. Cremer, blinded to clinical data and outcomes) analyzed CMR studies using commercially available software (CMR42; Circle Cardiovascular Imaging Inc., Calgary, Canada). A quantitative analysis of pericardial inflammation was performed on short-axis DHE sequences by manually contouring the pericardium. Normal septal myocardium was then selected as a reference region, and the signal >6 SD above normal myocardium was quantified (Figure 2 ). Inter-observer variability in 10 randomly selected cases (P. Cremer, A. Karwa) was excellent (r=0.95, P<0.001), whereas correlation with C-reactive protein for all patients was modest (rho=0.37, P=0.02).
Outcomes
Our primary outcome was clinical improvement with anti-inflammatory therapy at follow-up, defined as improvement in NYHA Class by at least one grade or resolution of right heart failure symptoms in NYHA Class I patients. Our secondary outcome was freedom from pericardiectomy.
Statistical Analysis
Statistical analyses were performed with JMP Version 10 (SAS Institute Inc., Cary, NC) and Stata Version 13.1 (StataCorp, College Station, TX). Normally distributed continuous variables were expressed as means with standard deviations, whereas non-normal continuous variables were expressed as medians (quartile 1, quartile 3). Categorical variables were expressed as percentages and totals. Between-group comparisons were made with Fisher Exact and Wilcoxon ranks sum tests, as appropriate. Correlation between quantitative analysis of pericardial DHE and qualitative reports was determined using Spearman's rank correlation coefficient (rho). Nominal logistic regression was used to create receiver-operating characteristic (ROC) curves for variables associated with clinical improvement. For continuous variables, the value that minimized the square root of [(1−sensitivity)2+(1−specificity)2] was then used as a dichotomous variable to determine sensitivity, specificity, positive predictive, and negative predictive values. Incremental prognostic value was defined as a statistically significant increase in global χ 2 , likelihood ratio tests, and area under the receiver-operating characteristic (AUROC) curve when pericardial DHE was added to a model that included clinical Representative patient with intense pericardial DHE. On this short-axis slice, the pericardium has been outlined (between red and green tracings), and normal septal myocardium has been outlined as a reference region (blue tracing). The pericardium is bright from increased DHE (A), and quantitative signal >6 standard deviations above normal myocardium is shown (B, yellow). DHE indicates delayed hyperenhancement. and laboratory variables. To account for overfitting of our model given few events, nominal logistic regression was used to create a propensity score to summarize clinical and laboratory variables associated with clinical improvement. The propensity score included age, chest pain, NYHA class, and Westergren sedimentation rates (WSR). A 2-sided P value <0.05 was considered statistically significant for all tests. Our Institutional Review Board approved this study.
Results
Patient Characteristics
In our cohort of 41 patients, most were male (83%), and the mean age was 58 years ( Table 1 ). The median follow-up was ≈1 year, and the majority of patients (61%) had a history of idiopathic pericarditis. At presentation, 39% were NYHA Class II, 34% were NYHA Class III, and 24% were NYHA Class I. Chest pain was initially present in 61% of patients. WSR and ultrasensitive C-reactive protein were above the upper limit of normal in 59% and 82% of patients, respectively. All patients had a diastolic septal bounce, 73% had a medial e′ velocity >9 cm/s, 38% had prominent expiratory diastolic flow reversal in the hepatic veins, 37% had annulus reversus, 33% had >25% respiratory variation in mitral inflow, and 30% had >40% respiratory variation in tricuspid inflow. On CMR, pericardial thickness was increased (>2 mm) on black blood sequences in 61% of patients and in 95% of patients on DHE sequences. When compared with quantitative analysis of pericardial DHE, qualitative interpretation from reports had a modest, but statistically significant correlation (rho=0.53, P<0.001). On qualitative interpretation, 46% of patients had moderate or severe pericardial inflammation while 41% had mild and 12% had no DHE.
Clinical, Laboratory, and Imaging Associations With Outcomes
There was no significant association with clinical improvement according to sex, age, or pathogenesis of constrictive pericarditis (Table 2) . Clinical improvement was significantly associated with chest pain (81% versus 40%, P=0.01) and a lower NYHA Class (II versus III, P=0.005). In the entire cohort, the majority of patients were prescribed colchicine (90%), NSAIDs (83%), and glucocorticoids (71%). Over half (59%) were taking all 3. Patients with clinical improvement tended to receive more aggressive treatment, though there were no statistically significant differences in type or dose of medication prescribed (Table2; ibuprofen moderate or severe pericardial DHE tended to be less likely to undergo pericardiectomy, but this association was not statistically significant (33% versus 59%, P=0.18). Among 38 patients with follow-up echocardiograms, 20 patients had clinical improvement, and these patients were also more likely to have echocardiographic improvement. At follow-up, a diastolic septal bounce was present in 50% of patients with clinical improvement compared with 94% of patients without clinical improvement (P=0.004), and medial e′ velocity was 9±3 cm/s compared with 11±3 cm/s for patients without clinical improvement (P=0.04). Fewer patients had prominent diastolic expiratory flow reversal in hepatic veins (22% versus 47%, P=0.16) and >25% respiratory variation in mitral inflow (15% versus 22%, P=0.69), but these associations were not statistically significant. Finally, in 32 patients with follow-up inflammatory markers (17 with clinical improvement), patients with clinical improvement had more dramatic decreases in WSR (Δ 12 versus 0 mm/hour, P=0.001) and ultrasensitive C-reactive protein (Δ 28.6 versus 3.2 mg/L, P=0.03).
Incremental Prognostic Value of Pericardial DHE to Predict Outcomes
To better delineate the magnitude and incremental value of the significant associations with clinical improvement, ROC curves were generated with variables associated with clinical improvement on univariable analysis (Figure 3 ).
Quantitative pericardial DHE performed best (AUROC curve of 0.83, P<0.0001), followed by WSR (AUROC curve of 0.77, P=0.001), then qualitative pericardial DHE (moderate or greater versus all others, AUROC of 0.76, P=0.001), then NYHA class (AUROC curve of 0.74, P=0.005), and chest pain (AUROC curve of 0.70, P=0.006). WSR and DHE were then sequentially added to a model, including clinical factors (age, chest pain, and NYHA class), and the final AUROC curve was 0.96 ( Figure 4) . Similarly, the global χ 2 of a model for clinical improvement significantly increased when WSR was added to clinical factors (P=0.03 for WSR) and increased even further when quantitative pericardial DHE (P=0.04 for quantitative DHE) was added in a step-wise fashion ( Figure 5 ). In contrast, qualitative reporting of pericardial DHE did not significantly increase the global χ 2 when added to clinical factors and WSR (P=0.13 for qualitative DHE). Given the possibility of overfitting our model, a propensity score was created to predict clinical resolution using age, chest pain, NYHA class, and WSR. As a single variable, this propensity score had an AUROC curve of 0.88 (global chi square 21.8, P<0.0001). When quantitative DHE was added to the propensity score, the AUROC curve increased to 0.94 (global chi square 30.0, model P<0.0001, P for quantitative DHE =0.004). Therefore, in patients who will receive anti-inflammatory therapy for constrictive pericarditis, quantitative analysis of pericardial DHE demonstrated incremental value in predicting clinical improvement. To better define the possible clinical utility of WSR and pericardial DHE in patients with constrictive pericarditis, the value with the best discriminatory ability was obtained from the ROC curves. For WSR, this value was 32 mm/hour, whereas the best cut point for quantitative pericardial DHE was 53 cm 3 . Patient outcomes according to pericardial DHE with this dichotomization are shown in Figure 6 . In patients with intense pericardial DHE, 15 of 19 demonstrated clinical improvement and 6 of these patients did not have WSRs >32 mm/hour. In isolation, a WSR >32 mm/hour demonstrated excellent specificity (95%) but poor sensitivity (48%) to predict clinical improvement. Conversely, pericardial DHE >53 cm 3 demonstrated improved sensitivity (71%) but decreased specificity (80%) when compared with WSR. When clinical factors were added to WSR and pericardial DHE, test characteristics were best with a sensitivity of 76% and specificity of 90% (Table 4) .
Discussion
To our knowledge, our study is the first hierarchical assessment of clinical, laboratory, and imaging variables associated with clinical improvement in patients with constrictive pericarditis. In addition, our study is the first quantitative assessment of the intensity of pericardial DHE in these patients. We have demonstrated that clinical improvement in patients with constrictive pericarditis is associated with chest pain, lower NYHA class, increased WSR, and increased pericardial DHE. Likewise, patients with chest pain, lower NYHA class, and increased pericardial DHE on quantitative analysis were less likely to have pericardiectomy. Finally, a quantitative assessment of pericardial DHE, but not qualitative reporting, provided incremental prognostic value to predict clinical improvement when added to clinical factors and inflammatory markers.
Comparison With Previous Studies
Our data are generally consistent with and expand on previous results on the utility of CMR to predict the reversibility of constrictive pericarditis. 4 We also demonstrated that patients with clinical improvement had higher inflammatory markers and increased pericardial DHE at baseline. Unlike previous work, we did not find a significant association between pericardial thickness and clinical improvement, though we did demonstrate a nonsignificant trend that patients with clinical improvement tended to have increased pericardial thickness. Even though our study was larger than the previous report, we may have been underpowered to detect this association. In addition, pericardial thickness may not correlate closely with active inflammation, and patients can have constrictive pericarditis, despite normal pericardial thickness. 12 We also did not find an association between the pathogenesis of constrictive pericarditis and clinical improvement, but the previous study had more patients with radiation heart disease, and these patients may be less likely to respond to anti-inflammatory therapy. In distinction to previous work, we used a quantitative assessment of pericardial DHE and were able to frame the additive importance of pericardial DHE within the context of background clinical factors and inflammatory markers. 
Limitations
Our study has many notable limitations. First, our study was small and retrospective from a single center. However, to our knowledge, our cohort is the largest collection of patients with constrictive pericarditis and CMR before the initiation of anti-inflammatory therapy. Also, 47 patients were excluded as they were referred directly for pericardiectomy, and this referral pattern suggests an opportunity to identify patients earlier in the disease course when they may still have reversible constrictive pericarditis. Second, our variables for echocardiographic diagnosis were similar, but not identical to recently proposed criteria. 10 Standardized noninvasive criteria for the diagnosis of constrictive pericarditis are evolving, 9, 13, 14 but have in part been limited by the lack of a true gold standard, and constrictive pericarditis remains a clinical diagnosis. Moreover, assessment of pericardial DHE has not been well established. Spatial resolution is limited to ≈2 mm, so differences in pericardial thickness of 1 mm are not reliable. The kinetics of gadolinium washout from the pericardium are also not well described, and the effects of different timings of gadolinium injection at various stages of pericardial diseases are unknown. Further, assessment of pericardial DHE with different machines across institutions has not been standardized. Nonetheless, pericardial DHE still performed well in discriminating patients who will improve, and we expect improved performance as these limitations are addressed.
Our study also included NYHA class I patients who may have milder constrictive physiology. These patients also benefited from anti-inflammatory therapy, but whether early treatment results in improved outcomes compared with watchful waiting is unclear. In addition, our follow-up was limited with a median of only 1 year. Therefore, we do not know whether patients with clinical improvement are truly cured or simply in remission. Finally, we lacked statistical power to assess cardiovascular mortality, and multicenter prospective studies could further elaborate on our findings.
Clinical Implications and Future Directions
In patients with constrictive pericarditis who will be treated with anti-inflammatory therapy, a quantitative assessment of pericardial DHE has incremental prognostic value to predict clinical improvement when added to clinical factors and WSR. However, our demonstration of incremental prognostic value should not mandate a quantitative assessment of pericardial DHE in all patients with constrictive pericarditis, and decisions should still be individualized. For example, patients who are NYHA Class I or who have significantly elevated WSRs seem likely to respond to anti-inflammatory therapy, and CMR for an assessment of pericardial inflammation could be reserved for patients who do not improve as expected. Conversely, in patients who are NYHA Class II or greater and in patients with WSRs that are not significantly elevated, increased pericardial DHE may provide insight into a patient who will still respond to anti-inflammatory therapy. In addition, for many patients, a qualitative assesment of pericardial DHE may be adequate. Of 25 patients with chest pain in our cohort, 14 had moderate or severe pericardial DHE on qualitiative analysis, and 13 of these patients had clinical improvement. Therefore, quantitative analysis may be most useful in patients with chest pain who have an indeterminant degree of pericardial DHE on subjective assessment. Moreover, though our correlation between subjective reports and quantitative analysis was significant (rho=0.53, P<0.001), the strength of association was only modest, and future study could focus on improving this correlation. If this correlation improved, then . Flow diagram of patient management according to intense pericardial DHE as a dichotomous variable according to the optimal value on the ROC curve. DHE indicates delayed hyperenhancement; ROC, receiver operating characteristic; and WSR, Westergren sedimentation rate. Pericardial Delayed Hyperenhancement in Constrictive Pericarditis few patients may clinically warrant quantitative pericardial DHE analysis, though there may still be a more widespread research application, given the objectivity.
In our study, patients were treated aggressively with over half of patients prescribed triple therapy (colchicine, NSAIDs, and glucorticoids). Of note, we assessed associations with clinical improvement, but we did not evaluate whether CMR results can effectively guide therapy. In patients with constrictive pericarditis being considered for anti-inflammatory therapy, future studies could investigate whether intensity and duration of treatment guided by CMR results can improve outcomes.
Conclusions
In patients with constrictive pericarditis, chest pain, lower NYHA class, increased WSR, and increased pericardial DHE were associated with clinical improvement with anti-inflammatory therapy. A quantitative assessment of pericardial DHE, but not qualitative reporting, had incremental value to predict clinical improvement when added to clinical factors and WSR.
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